Journey MedicalDERM +1.46%62 Days Payable is 125.13 as of Mar. 2026, which is 42% below its 10-year median of 217.19. GuruFocus rates DERM with a GF Score™ of 62/100 and a GF Value™ of $4.17 (Significantly Overvalued). The stock has 3 warning signs investors should review. Among 923 Drug Manufacturers companies, Journey Medical ranks better than 81.69% on this metric.
The historical rank and industry rank for Journey Medical's Days Payable or its related term are showing as below:
DERM'
s Days Payable Range Over the Past 10 Years
Min: 50.82 Med: 217.19 Max: 439.51
Current: 182.13
During the past 7 years, Journey Medical's highest Days Payable was 439.51. The lowest was 50.82. And the median was 217.19.
DERM's Days Payable is ranked better than 81.69% of 923
companies
in the Drug Manufacturers industry
Industry Median: 90.98
vs DERM: 182.13
Journey Medical's Days Payable
declined
from Mar. 2025 (290.08) to Mar. 2026 (125.13).
It may suggest that Journey Medicalaccelerated paying its suppliers.
Journey Medical Days Payable Related Terms
Journey Medical Days Payable Historical Data
* Premium members only.
The historical data trend for Journey Medical's Days Payable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Journey Medical's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Journey Medical Days Payable vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Journey Medical's Days Payable distribution charts can be found below:
* The bar in red indicates where Journey Medical's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
Journey Medical's Days Payable for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Journey Medical (DERM) has a Days Payable of 125.13 as of Mar. 2026. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Journey Medical and its competitors. This is 42% below median its historical median of 217.19. Over the past decade, Journey Medical's Days Payable has ranged from 50.82 to 439.51. According to the industry distribution chart, Journey Medical ranks #169 out of 923 companies in the Drug Manufacturers industry, placing it in the top 18.3%.
Is Journey Medical's Days Payable too high?
Journey Medical's current Days Payable of 125.13 is 42% below median its 10-year median of 217.19. Over the past 10 years, this metric has ranged from a low of 50.82 to a high of 439.51. The Drug Manufacturers industry median Days Payable is 90.98. Journey Medical's value of 125.13 is 37.5% above this industry median. Based on the distribution chart, Journey Medical ranks #169 out of 923 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Journey Medical has a GF Score™ of 62/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Journey Medical's Days Payable compare to LFCR and ANIK?
According to the Drug Manufacturers industry distribution chart, Journey Medical ranks #169 out of 923 companies for Days Payable. This places Journey Medical in the top 18% of its industry — outperforming the majority of peers. The industry median Days Payable is 90.98. Journey Medical's value of 125.13 is 37.5% above this benchmark. Historically, Journey Medical's own Days Payable has ranged from 50.82 to 439.51 over the past decade. While the company's 10-year median is 217.19 vs. the industry median of 90.98, Journey Medical has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Drug Manufacturers company?
The median Days Payable among Drug Manufacturers companies is 90.98, based on 923 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Journey Medical's current Days Payable of 125.13 is 37.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Journey Medical and its competitors. For the Drug Manufacturers industry, the median Days Payable is 90.98 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Journey Medical's current Days Payable is 125.13, which is 42% below median its own 10-year median of 217.19. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Journey Medical stock overvalued right now?
Based on GuruFocus' analysis, Journey Medical (DERM) is currently considered Significantly Overvalued. The stock's GF Value™ is $4.17, compared to a current price of $6.95 — trading 66.7% above its estimated fair value. The current Days Payable is 125.13, which is 42% below median its 10-year median of 217.19 and 37.5% above the Drug Manufacturers industry median of 90.98. Journey Medical's overall GF Score™ is 62/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Journey Medical (DERM), the current Days Payable is 125.13 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Journey Medical (DERM) Overvalued in 2026?
Based on GuruFocus' analysis, Journey Medical stock appears to be overvalued.
The current stock price of $6.95 is trading 66.7% above its estimated GF Value™ of $4.17.
GuruFocus considers Journey Medical to be Significantly Overvalued.
Key valuation signals for DERM:
Days Payable: 125.13 (42% below median its 10-year median of 217.19)
GF Value™: $4.17 vs. price of $6.95 (66.7% above fair value)
Industry Position: 37.5% above the Drug Manufacturers median (#169 of 923)
No single metric tells the full story. See the DERM stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Journey Medical Corp is a commercial-stage pharmaceutical company that focuses on the selling and marketing of U.S. Food and Drug Administration (FDA) approved prescription pharmaceutical products for the treatment of dermatological conditions. Its current product portfolio includes FDA-approved prescription drugs for dermatological conditions that are marketed in the U.S. The company views its operations and manages its business in one segment, which reflects products for the treatment of dermatological conditions. The dermatological segment derives revenues from the sale of branded and authorized general prescription products that treat certain dermatological conditions.
62GF Score
Get the complete analysis for DERM
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
DERM has been successfully added to your 
